Literature DB >> 21550045

Ramifications of adolescent menstrual cycles ≥42 days in young adults.

John A Morrison1, Charles J Glueck, Stephen Daniels, Ping Wang, Davis Stroop.   

Abstract

OBJECTIVE: To determine to what degree annual reports from ages 14 to 19 years of menstrual cycles ≥42 days would be associated with increased body mass index (BMI), waist circumference, glucose, insulin, and homeostasis model assessment insulin resistance (HOMA-IR) at ages 14-25 years.
DESIGN: Prospective 11-year follow-up from ages 14 to 25 years.
SETTING: Urban-suburban schools, post-high school. PATIENT(S): A total of 370 schoolgirls. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): BMI, waist, insulin, glucose, HOMA-IR. RESULT(S): From ages 14 to 19 years, 269 girls had 0/6 annual reports of menstrual cycles ≥42 days, 74 had 1, 19 had 2, and 8 had ≥3. Among these four categories, girls with ≥3 annual reports had highest free T and DHEAS at age 14, highest BMI and waist at ages 14, 19, and 25, highest insulin at age 25, and highest glucose and HOMA-IR at age 24 years. The number of annual reports of menstrual cycles ≥42 days was positively related to change in BMI and waist and inversely with change in high-density lipoprotein cholesterol from ages 14 to 25 years. CONCLUSION(S): Three or more annual reports of menstrual cycles ≥42 days during ages 14-19 are associated with high BMI, waist circumference, insulin, glucose, and HOMA-IR at ages 14-25 years.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21550045      PMCID: PMC3758878          DOI: 10.1016/j.fertnstert.2011.04.005

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  35 in total

1.  Racial divergence in adiposity during adolescence: The NHLBI Growth and Health Study.

Authors:  S Y Kimm; B A Barton; E Obarzanek; R P McMahon; Z I Sabry; M A Waclawiw; G B Schreiber; J A Morrison; S Similo; S R Daniels
Journal:  Pediatrics       Date:  2001-03       Impact factor: 7.124

2.  Insulin, androgen, and gonadotropin concentrations, body mass index, and waist to hip ratio in the first years after menarche in girls with regular menstrual cycles, irregular menstrual cycles, or oligomenorrhea.

Authors:  M H van Hooff; F J Voorhorst; M B Kaptein; R A Hirasing; C Koppenaal; J Schoemaker
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

3.  Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.

Authors:  Kate A Marsh; Katharine S Steinbeck; Fiona S Atkinson; Peter Petocz; Jennie C Brand-Miller
Journal:  Am J Clin Nutr       Date:  2010-05-19       Impact factor: 7.045

4.  Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).

Authors:  C J Glueck; P Wang; R Fontaine; T Tracy; L Sieve-Smith
Journal:  J Adolesc Health       Date:  2001-09       Impact factor: 5.012

5.  Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin.

Authors:  M H van Hooff; F J Voorhorst; M B Kaptein; R A Hirasing; C Koppenaal; J Schoemaker
Journal:  Fertil Steril       Date:  2000-07       Impact factor: 7.329

6.  Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.

Authors:  L Ibáñez; C Valls; N Potau; M V Marcos; F de Zegher
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

7.  Impaired glucose tolerance in obese white children and adolescents: three to five year follow-up in untreated patients.

Authors:  M Kleber; G deSousa; S Papcke; M Wabitsch; T Reinehr
Journal:  Exp Clin Endocrinol Diabetes       Date:  2010-09-08       Impact factor: 2.949

8.  Impact of timing of pubertal maturation on growth in black and white female adolescents: The National Heart, Lung, and Blood Institute Growth and Health Study.

Authors:  F M Biro; R P McMahon; R Striegel-Moore; P B Crawford; E Obarzanek; J A Morrison; B A Barton; F Falkner
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

9.  Menstrual irregularity: a possible clinical marker of metabolic dysfunction in women with class III obesity.

Authors:  F A C Souza; R Dias; C E Fernandes; F Pimentel; D Dias
Journal:  Gynecol Endocrinol       Date:  2010-10       Impact factor: 2.260

10.  Hyperinsulinemia and metabolic syndrome at mean age of 10 years in black and white schoolgirls and development of impaired fasting glucose and type 2 diabetes mellitus by mean age of 24 years.

Authors:  John A Morrison; Charles J Glueck; Muhammad Umar; Stephen Daniels; Lawrence M Dolan; Ping Wang
Journal:  Metabolism       Date:  2010-01-22       Impact factor: 8.694

View more
  4 in total

1.  Influence of Contraception Use on the Reproductive Health of Adolescents and Young Adults.

Authors:  Richard J Fehring; Thomas Bouchard; Maria Meyers
Journal:  Linacre Q       Date:  2018-04-25

2.  Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19 years: the Cincinnati National Growth and Health Study.

Authors:  John A Morrison; Charles J Glueck; Stephen R Daniels; Paul S Horn; Ping Wang
Journal:  Metabolism       Date:  2012-04-16       Impact factor: 8.694

Review 3.  Criteria for Diagnosis of Polycystic Ovary Syndrome during Adolescence: Literature Review.

Authors:  Alexia S Peña; Ethel Codner; Selma Witchel
Journal:  Diagnostics (Basel)       Date:  2022-08-10

4.  Reproductive history and risk of type 2 diabetes mellitus in postmenopausal women: findings from the Women's Health Initiative.

Authors:  Erin S LeBlanc; Kristopher Kapphahn; Haley Hedlin; Manisha Desai; Nisha I Parikh; Simin Liu; Donna R Parker; Matthew Anderson; Vanita Aroda; Shannon Sullivan; Nancy F Woods; Molly E Waring; Cora E Lewis; Marcia Stefanick
Journal:  Menopause       Date:  2017-01       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.